Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Day One Biopharmaceuticals, Inc.

$21.53

+0.03 (+0.14%)

C 57Pipeline Score Fair Value Pharma · Commercial
Market Cap
2.22 B
EPS
-1.04
P/E Ratio
-
Value Trade
64.31 M
SEC Financials
Q4 2025

  • Dilution Risk

    5%

  • Revenue

    53.72 M

  • R&D Expenses

    40.95 M

  • Operating CF

    -25.94 M

  • Total Assets

    507.83 M

  • Total Liabilities

    66.67 M

  • Equity

    441.16 M

  • D/E Ratio

    12,345

0.28 %
Week
0.7 %
1 Month
76.48 %
3 Month
188.22 %
6 Month
-13.88 %
5 Year
-13.88 %
All Time
Cash Data
Healthy

  • Cash Position

    441.11 M

  • Monthly Burn

    8.65 M

  • Runway

    48.1 mo

  • Burn Trend

    Stable

  • SEC Filing

    Apr 17, 2026
Overview
Volume
2.99 M
52 Week Range
5.64 - 21.53
% held by Insiders
26.57 %
% held by Institutions
68.56 %
Enterprise Value
1.79 B
Total Shares
102.62 M
Short %
8.61 %
Float Shares
76.45 M
Company Description
HQ: 1800 SIERRA POINT PARKWAY, SUI...
Employees:178
https://www.dayonebio.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Unlock the full Catalyst Timeline
Past FDA Catalysts & PDUFA Decisions
Date Drug Catalyst Stage Outcome Reaction Event Move % Best Trade %
2024-12-31
Pimasertib
Phase 1/2 data readout
Phase 1/2
—
–
–
–
2024-12-31
Pimasertib
Phase 1/2 data readout
Phase 1/2
—
–
–
–
2024-12-31
Pimasertib
Phase 1/2 data readout
Phase 1/2
—
–
–
–
Unlock 1 more historical catalysts
Drug Pipeline Intelligence
C57
Pipeline Score
$2.7B
Pipeline Value
Fair Value
Valuation Signal
9
Drugs Scored
1.2x
rNPV / MCap
Top 85%
Small Cap
(rank 138 of 912)
Percentile Rank
Day One Biopharmaceuticals, Inc. carries a moderate pipeline score (57/100), with $4.1B risk-adjusted pipeline value, led by Tovorafenib in Low-grade Glioma (Phase 3).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Tovorafenib
Small molecule		Low-grade GliomaPhase 3NCT0556679590% $2.1B ACTIVE NOT_RECRUITING 559 AVERAGE C (56) Jun 1, 2031MODERATE_RISKMEDIUM
May 26, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
OJEMDA (tovorafenib)
BreakthroughPriorityAccelerated+2
pediatric low-grade glioma (pLGG)
Phase 2
2025-11-24

patients off therapy: 77%; median time to next treatment: 3.5 years; overall response rate: 53% (40/76); median duration of response: 19.4 months (95% CI [13.8-27.2]); time to response: 5.4 months (range [1.6-17.5]); median progression free survival: 16.6 months (10.9-22.0)

Read More

Day One Announces Three Year Follow-Up Data From OJEMDA (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting Updated data expands clinically meaningful results available from

Read More
OJEMDA (tovorafenib)
BreakthroughPriorityAccelerated+2
pediatric low-grade glioma (pLGG)
Phase 2
2025-11-24

patients off therapy: 77%; median time to next treatment: 3.5 years; overall response rate: 53% (40/76); median duration of response: 19.4 months (95% CI [13.8-27.2]); time to response: 5.4 months (range [1.6-17.5]); median progression free survival: 16.6 months (10.9-22.0)

Read More

Day One Announces Three Year Follow-Up Data From OJEMDA (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting Updated data expands clinically meaningful results available from

Read More
OJEMDA (tovorafenib)
BreakthroughPriorityAccelerated+2
pediatric low-grade glioma (pLGG)
Phase 2
2025-11-24

patients off therapy: 77%; median time to next treatment: 3.5 years; overall response rate: 53% (40/76); median duration of response: 19.4 months (95% CI [13.8-27.2]); time to response: 5.4 months (range [1.6-17.5]); median progression free survival: 16.6 months (10.9-22.0)

Read More

Day One Announces Three Year Follow-Up Data From OJEMDA (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting Updated data expands clinically meaningful results available from

Read More
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in DAWN
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
DAWN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How DAWN ranks across every disease it competes in
Competitive Position is a premium feature
See how DAWN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial